The earnings call reflected a period of significant strategic transformation for Tivic Health, with promising developments in their transition to a diversified immunotherapeutics company. The acquisition of Entolimod and advancements toward commercialization present considerable growth opportunities. However, the company faces financial challenges with declining revenue and cash reserves, balancing the positive strategic shifts.

Company Guidance -

Q2 2025

In the first quarter of 2025, Tivic Health Systems reported a significant strategic transition, focusing on their evolution from a single-product company to a diversified immunotherapeutics entity. The company's revenue decreased to $70,000 from $334,000 the previous year, reflecting an 81% drop in unit sales due to a 92% reduction in advertising spend, as resources were redirected towards the Statera licensing agreement. Gross margins improved to 72% from 50%, and operating expenses remained steady at $1.6 million. Tivic reported a net loss of $1.5 million, consistent with the previous year, and had cash reserves of $669,000. They secured $8.4 million in strategic financing and a $25 million equity line of credit to support their transformation, particularly advancing the development of their newly acquired late-stage immunomodulatory drug candidate, Entolimod. Additionally, Tivic plans to enhance their vagus nerve stimulation program, with further updates expected in the coming months.

Strategic Transition to Diversified Immunotherapeutics

Tivic Health has transitioned from a single product company to a diversified immunotherapeutics company, focusing on diseases related to immune system dysregulation.

Acquisition of Entolimod and Entolasta

Tivic Health secured exclusive worldwide rights to late-stage immunomodulatory drug candidate Entolimod and its derivative Entolasta, representing a significant value creation opportunity.

Increased Gross Margins

Gross margins increased from 50% to 72% due to reduced product support and fulfillment costs.

Strategic Financing and Capital Infusion

Tivic Health secured $8.4 million in tranche funding, a $25 million equity line of credit, and raised $1.7 million through an ATM program to support its strategic transformation.

FDA Fast Track and Orphan Drug Status

Entolimod received Fast Track and orphan drug status from the FDA for acute radiation syndrome (ARS), indicating potential for accelerated pathways and emergency use designations.

Tivic Health Systems (TIVC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TIVC Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 18, 2025	2025 (Q2)	- / -	-0.32	―	―	―
May 15, 2025	2025 (Q1)	- / -2.52	-17.17	85.33% (+14.65)	―
Mar 21, 2025	2024 (Q4)	- / -2.65	154.36	-101.72% (-157.01)	―
Nov 15, 2024	2024 (Q3)	- / -3.91	-25.16	84.46% (+21.25)	―
Aug 14, 2024	2024 (Q2)	- / -5.44	-119	95.43% (+113.56)	―
May 15, 2024	2024 (Q1)	- / -17.17	-187	90.82% (+169.83)	―
Mar 25, 2024	2023 (Q4)	- / 154.36	-391	139.48% (+545.36)	―
Nov 14, 2023	2023 (Q3)	-119.00 / -25.16	-459	94.52% (+433.84)	―
Aug 14, 2023	2023 (Q2)	-136.00 / -119.00	-544	78.13% (+425.00)	―	―
May 15, 2023	2023 (Q1)	- / -	-23	―	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TIVC Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 15, 2025	$4.32	$4.27	-1.16%
Mar 21, 2025	$3.55	$3.41	-3.94%
Nov 15, 2024	$6.24	$4.92	-21.15%
Aug 14, 2024	$5.30	$4.93	-6.98%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Tivic Health Systems (TIVC) report earnings?

Tivic Health Systems (TIVC) is schdueled to report earning on Aug 18, 2025, TBA (Confirmed).

What is Tivic Health Systems (TIVC) earnings time?

Tivic Health Systems (TIVC) earnings time is at Aug 18, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TIVC EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing